Stockscreener 앱 받기
73.52
6.06%
4.20
시간 외 거래:
74.60
1.08
+1.47%
전일 마감가:
$69.32
열려 있는:
$70.06
하루 거래량:
1.14M
Relative Volume:
1.13
시가총액:
$6.48B
수익:
$5.07M
순이익/손실:
$-186.75M
주가수익비율:
-31.39
EPS:
-2.3424
순현금흐름:
$-160.43M
1주 성능:
+4.74%
1개월 성능:
+2.17%
6개월 성능:
+33.43%
1년 성능:
+181.69%
1일 변동 폭
$70.06
$73.89
1주일 범위
$68.00
$73.89
52주 변동 폭
$23.65
$77.00
Cg Oncology Inc Stock (CGON) Company Profile
명칭
Cg Oncology Inc
전화
(949) 409-3700
주소
3000 PEGASUS PARK DRIVE, DALLAS
Compare CGON vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
73.52 | 6.11B | 5.07M | -186.75M | -160.43M | -2.3424 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-11 | 개시 | Wedbush | Outperform |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-10-08 | 개시 | Guggenheim | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-05-02 | 개시 | JP Morgan | Overweight |
| 2025-04-16 | 개시 | Scotiabank | Sector Perform |
| 2025-01-07 | 개시 | TD Cowen | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-09-23 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-28 | 개시 | ROTH MKM | Buy |
| 2024-06-28 | 개시 | BofA Securities | Buy |
| 2024-02-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-02-20 | 개시 | Goldman | Neutral |
| 2024-02-20 | 개시 | Morgan Stanley | Overweight |
| 2024-02-14 | 개시 | H.C. Wainwright | Buy |
모두보기
Cg Oncology Inc 주식(CGON)의 최신 뉴스
CG Oncology bladder cancer trial results published in Lancet - Investing.com
CG Oncology Announces Lancet Oncology Publication of Phase 3 BOND-003 Cohort C Results for Cretostimogene in High-Risk BCG-Unresponsive Bladder Cancer - Quiver Quantitative
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology - GlobeNewswire Inc.
BlackRock, Inc. (CGON) discloses 6.8% beneficial ownership in CG Oncology - Stock Titan
CGON (CGON) filer discloses 50,000-share sale plan and recent stock sales - Stock Titan
CG Oncology Market Sentiment - Benzinga España
CG Oncology Inc (CGON) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CG Oncology, Inc. Revenue Breakdown – NASDAQ:CGON - TradingView
CGON|CG Oncology Inc|Price:69.795|Chg%:+0.475 - TradingKey
CG Oncology Inc (CGON) Institutional Confidence - TradingKey
CG Oncology Inc (CGON) Cash Flow - TradingKey
TradingKey - TradingKey
CG Oncology Inc (CGON) Income Statement - TradingKey
CG Oncology Inc (CGON) Valuation: PE, PB & Fair Value Analysis - TradingKey
CG Oncology Inc (CGON) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CG Oncology Inc (CGON) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CG Oncology Inc (CGON) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Midday Stock Roundup: Shares of loanDepot up 7% - Orange County Business Journal
CG Oncology Inc (CGON) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Intratumoral Cancer Therapies Market to Reach USD 3.15 Billion - openPR.com
CG Oncology (CGON) Rises 2.6% as Biotech Sentiment Lifts Oncology-Focused NamesThematic ETF Flow - dars.gov.et
CGON (CGON) insider files to sell 50,000 shares after option exercise - Stock Titan
CG Oncology appoints David Fela as vice president to strengthen quality control focus - Traders Union
Biotech Darling CG Oncology Suddenly Falls Out Of Favor - TipRanks
CG Oncology: Priced To Perfection On Future Pipeline Success - Seeking Alpha
CG Oncology director Leonard Post disposes of 1,000 shares for $71,170 - Bitget
CG Oncology (CGON) Surges 3.4% as Bullish Momentum Builds Above Key SupportRounding Bottom - dars.gov.et
CG Oncology (CGON) director sells 1,000 shares at $71.17 - Stock Titan
ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter - Sahm
Ani Pharmaceuticals Announces Intent To Appeal Rulings In CG Oncology Matter - TradingView
ANI Pharmaceuticals to Appeal Delaware Ruling Denying Post-Trial Motions in CG Oncology Asset Dispute - Quiver Quantitative
Form 144 CG ONCOLOGY For: 15 July By Investing.com - Investing.com Nigeria
CG Oncology, Inc. SEC Filing (Jul 15, 2026) - Stock Titan
CG Oncology: Advancing Toward a Potential Breakthrough in Bladder Cancer Treatment - Kalkine
CG Oncology (CGON) director exercises options, sells 24,165 shares - Stock Titan
CG Oncology (CGON) Declines Moderately as Biotech Sector Faces HeadwindsMomentum ETF - dars.gov.et
CG Oncology Stock Stumbles After Hitting Fresh Peak - TipRanks
CG Oncology Stock Gains 12% in Three Months: What's Driving It? - Yahoo Finance
Form DEF 14A CG Oncology Inc For: 10 July By Investing.com - Investing.com Australia
Form 144 CG Oncology For: 10 July By Investing.com - Investing.com South Africa
Cognition Therapeutics (NASDAQ: CGON) insider plans sale of 20,237 shares - Stock Titan
Truist Financial Maintains CG Oncology(CGON.US) With Buy Rating - Moomoo
CG Oncology (CGON) Investor presentation Summary - Quartr
CG Oncology (CGON) Jefferies Global Healthcare Conference 2026 Summary - Quartr
CG Oncology (CGON) Bank of America Global Healthcare Conference 2026 Summary - Quartr
A Quick Look at Today's Ratings for CG Oncology(CGON.US), With a Forecast Between $77 to $108 - Moomoo
CGONCg Oncology Inc Options - Finviz
CGON,QURE Volatility & Greeks - Finviz
CG Oncology Stock (CGON) Opinions on Director's Massive Share Purchase - Quiver Quantitative
CG Oncology | 4: Statement of changes in beneficial ownership of securities-Director POST LEONARD E - Moomoo
Form 144 CG ONCOLOGY INC For: 1 July By Investing.com - Investing.com UK
Cg Oncology Inc (CGON) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):